Axokine: Phase II

In a 12-week U.S. Phase II dose ranging trial of 170 severely or morbidly obese patients, self-administered subcutaneous

Read the full 186 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE